RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)

The summary for the RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed): The overarching objective of this concept is to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research lab, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation.

Federal Grant Title:	RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education, Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-24-029
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.393, 93.394, 93.395, 93.396, 93.399
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 4th, 2024
Original Application Deadline:	November 4th, 2024
Posted Date:	July 29th, 2024
Creation Date:	July 29th, 2024
Archive Date:	December 10th, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	July 29th, 2024

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-029.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed); • Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed); • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed...; • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional); • NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed); • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional); • Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed); • Coordinating Center to Support Consortium for Neuroscience Alzheimers Disease (AD) and AD-...; • Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials o...; • Administrative Supplements to Promote Diversity in Research and Development Small Business...